Aliquots Archives
Immune landscape in adrenal cancer
Dec. 14, 2021—The profile of immune-related gene expression and tumor-infiltrating immune cells in adrenocortical cancer suggests targets for new treatment strategies.
Oral microbes and gastric cancer
Dec. 13, 2021—Studies in three large population cohorts that include Asian, African American and European American people support a role for the oral microbiota — the collection of microbial species in the mouth — in gastric cancer development.
Cell signaling targets in leukemia
Dec. 9, 2021—Vanderbilt researchers identified a critical role for IL-1beta signaling in leukemia cells with a certain mutation, suggesting this pathway may be a good target for novel treatments.
Prostate cancer treatment regret
Dec. 9, 2021—Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.
AI predicts 24-hour hospital discharge
Nov. 16, 2021—Vanderbilt researchers used a machine learning algorithm and data from more than 26,000 hospital stays to predict who would and would not be discharged over the next 24 hours.
Who’s who in the respiratory landscape
Nov. 15, 2021—A metatranscriptomics method developed by Vanderbilt researchers simultaneously characterizes viruses, microbiome and host response in nasal swabs, opening opportunities to explore molecular interactions directly in clinical samples.
The power of white matter
Nov. 11, 2021—Using a novel analysis of fMRI data, Vanderbilt researchers discovered intriguing patterns of signals in the brain’s white matter, the “conduit” for relaying signals between different brain regions.
New way to bEET insulin resistance
Nov. 11, 2021—Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.
Shifts in neuroendocrine cancer clinical trial design
Nov. 2, 2021—Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.
Breast cancer survivors: eat nuts
Nov. 1, 2021—Breast cancer survivors who reported eating nuts regularly had 50% reduced risk of breast cancer recurrence, metastasis or mortality, Vanderbilt epidemiologists found in Shanghai Breast Cancer Survival Study.
Pancreatic beta-cell booster
Oct. 28, 2021—Blocking inflammatory signaling improves beta-cell characteristics in a mouse model of type 2 diabetes and may provide added benefits to GLP-1R diabetes medications.
The challenge of rejection
Oct. 28, 2021—Minimizing variation in how rejection is diagnosed and creating standardized surveillance protocols may help inform best practices in pediatric heart transplants.
